Clinical trial
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
NCT00444951 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00444951 |
|---|---|
| Title | Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia |
| Official title | Evaluation of the Response to a Single Dose of Menactra® in Adolescents Aged 16 to 19 Years Who Previously Received One Dose of Quadrivalent (A, C, Y, W 135) and at Least One Dose of Bivalent (A, C) Meningococcal Polysaccharide Vaccine in Saudi Arabia. |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neisseria Meningitidis, Meningococcal Infections |
| Intervention type | Biological |
| Interventions | Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine, Mencevax®: Group A, W135 and Y polysaccharide meningococcal vaccine |
| Enrollment | 450 |
| Start date | Feb 1, 2007 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Mar 8, 2007 |
| Last update posted | Jul 14, 2015 |
| Countries | Saudi Arabia |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: